KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 132 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $6,976,000 | -9.6% | 2,051,899 | 0.0% | 0.00% | -33.3% |
Q2 2018 | $7,715,000 | -8.1% | 2,051,899 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $8,393,000 | -12.0% | 2,051,899 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $9,541,000 | -34.5% | 2,051,899 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $14,568,000 | +0.5% | 2,051,899 | +2.3% | 0.01% | 0.0% |
Q2 2017 | $14,502,000 | +38.3% | 2,005,796 | +17.9% | 0.01% | +50.0% |
Q1 2017 | $10,484,000 | +5.1% | 1,701,935 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $9,973,000 | +15.5% | 1,701,935 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $8,632,000 | -23.4% | 1,701,935 | 0.0% | 0.00% | -20.0% |
Q2 2016 | $11,267,000 | +41.8% | 1,701,935 | 0.0% | 0.01% | +25.0% |
Q1 2016 | $7,948,000 | -13.1% | 1,701,935 | -6.1% | 0.00% | -20.0% |
Q4 2015 | $9,150,000 | +175.9% | 1,811,935 | +92.4% | 0.01% | +150.0% |
Q3 2015 | $3,316,000 | -64.7% | 941,935 | 0.0% | 0.00% | -60.0% |
Q2 2015 | $9,401,000 | +22.0% | 941,935 | +55.6% | 0.01% | +25.0% |
Q1 2015 | $7,708,000 | – | 605,520 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management I, LLC | 1,312,006 | $22,357,000 | 15.70% |
VHCP Management, LLC | 1,000,273 | $17,045,000 | 8.86% |
HARVEY CAPITAL MANAGEMENT INC | 915,800 | $15,605,000 | 6.22% |
Baupost Group | 6,310,850 | $107,537,000 | 2.60% |
SECTORAL ASSET MANAGEMENT INC | 3,537,590 | $60,281,000 | 2.48% |
INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 587,504 | $10,011,000 | 2.31% |
Knoll Capital Management, LLC | 200,000 | $3,408,000 | 1.76% |
Camber Capital Management LP | 1,250,000 | $21,300,000 | 1.67% |
NORTHPOINTE CAPITAL LLC | 877,875 | $14,958,000 | 1.52% |
DAFNA Capital Management LLC | 100,000 | $1,704,000 | 1.46% |